Evidence map›Paper›PMID 40288859›Full record

ArticleThe Lancet. Rheumatology2025

Tumour necrosis factor inhibitor safety in rheumatoid arthritis with early-stage cancer.

Jeffrey A Sparks, Namrata Singh

Abstract read
In one paragraph

Article in The Lancet. Rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeffrey A SparksDivison of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA. Electronic address: jsparks@bwh.harvard.edu.
Namrata SinghDivision of Rheumatology, Department of Internal Medicine, University of Washington, Seattle, WA, USA.

Funding

Improving shared decision-making around the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerK23AR079588 · NIAMS · UNIVERSITY OF WASHINGTON · PI Namrata Singh · 2022 to 2026
$821k
Impact of rheumatoid arthritis on survival in older adults with cancerR03AG082857 · NIA · UNIVERSITY OF WASHINGTON · PI SINGH, NAMRATA · 2023 to 2024
$289k
NIAMS NIH HHS K23 AR079588NIA NIH HHS R03 AG082857
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40288859
PMCPMC13225136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.